Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

259
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
259
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

429
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypersensitivity pneumonitis.

Tuberkuloz ve toraks·2026
Same authorSame journal

Successful and practical pirfenidone desensitization.

Tuberkuloz ve toraks·2026
Same author

Clinical and Functional Heterogeneity of COPD Phenotypes: A Multicenter Study from Turkey (DIPTUR Study).

Medicina (Kaunas, Lithuania)·2026
Same author

Cough burden and quality of life in patients with progressive pulmonary fibrosis: A multicenter observational study.

Respiratory medicine·2025
Same author

Evaluation of exacerbation severity in patients with COPD exacerbations according to the GOLD 2023 report.

Expert review of respiratory medicine·2025
Same author

The Prevalence of Previous Coronavirus Disease-19 in Patients with Pulmonary Thromboembolism and Its Effect on Embolism Severity.

Journal of clinical medicine·2025
Same journal

Treatment of severe tracheobronchopathia osteochondroplastica: Application of endobronchial argon plasma coagulation, presentation of three cases and literature review.

Tuberkuloz ve toraks·2026
Same journal

Fractional exhaled nitric oxide and practical points in asthma diagnosis and management.

Tuberkuloz ve toraks·2026
Same journal

High-resolution CT findings of culture-confirmed enterococcal pneumonia: A two-center retrospective study.

Tuberkuloz ve toraks·2026
Same journal

Explainable benchmarking of U-Net variants for lung segmentation on chest radiographs.

Tuberkuloz ve toraks·2026
Same journal

Short-term changes in serum total protein and albumin and clinical outcomes in acute exacerbation of interstitial lung diseases.

Tuberkuloz ve toraks·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

223

Progressive pulmonary fibrosis (PPF).

Dildar Duman1

  • 1Department of Chest Diseases, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, İstanbul, Türkiye.

Tuberkuloz Ve Toraks
|December 20, 2022
PubMed
Summary
This summary is machine-generated.

Progressive pulmonary fibrosis (PPF) is a worsening lung condition. Nintedanib is conditionally recommended for PPF treatment, while pirfenidone requires further study.

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

321
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

713

Related Experiment Videos

Last Updated: Aug 16, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

223
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

321
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

713

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Radiology
  • Pharmacology

Background:

  • Progressive pulmonary fibrosis (PPF) is characterized by worsening respiratory symptoms, functional decline, and radiological progression in patients with interstitial lung disease.
  • It is diagnosed when at least two of these three criteria are met within a year, excluding idiopathic pulmonary fibrosis (IPF).
  • PPF was previously termed progressive fibrotic interstitial lung diseases.

Approach:

  • This review discusses the diagnostic and therapeutic strategies for PPF.
  • It incorporates recent updates and new nomenclature for the condition.
  • The approach focuses on current evidence and clinical guidelines.

Key Points:

  • Nintedanib has a conditional recommendation for treating PPF.
  • Pirfenidone's role in PPF treatment requires additional research and evidence.
  • Early diagnosis and appropriate management are crucial for PPF patients.

Conclusions:

  • The review provides an updated overview of PPF diagnosis and management.
  • It highlights the current therapeutic recommendations and areas needing further investigation.
  • Understanding PPF's evolving definition and treatment landscape is essential for clinicians.